bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – What’s Next?

bioMerieux (OTCMKTS:BMXMF)’s share price gapped up before the market opened on Monday. The stock had previously closed at $84.87, but opened at $91.35. bioMerieux shares last traded at $91.35, with a volume of 10 shares traded.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Morgan Stanley reissued an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a research note on Monday, September 28th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Five equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce”.

bioMerieux Stock Up 4.0%

The company’s fifty day moving average price is $84.78 and its two-hundred day moving average price is $86.14.

bioMerieux Company Profile

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.